What does ipamorelin cost in each channel?
Prices in US dollars at the verification date. Ranges are published list or program prices where a primary source exists; notes say when a figure is a typical market range instead.
| Channel | Price (USD) | Notes |
|---|---|---|
| With insurance | Not published | Not covered. Medicare Part D and commercial pharmacy benefits cover FDA approved drugs for accepted indications; compounded or unapproved peptides are paid in cash. [3] |
| Compounded pharmacy | Not published | No lawful compounded price. Ipamorelin was placed on 503A Category 2 in September 2023, its 503A nomination was later withdrawn, and it is not on the bulks list or a component of an approved drug. Products sold as research chemicals for human use are unapproved drugs and are unverified for identity or purity. [1] [2] [4] |
Why is there no price for ipamorelin?
Many clinics offer ipamorelin anyway. FDA has also found compounding pharmacies and an online seller offering it. [5] [6] [7] [8]
Clinics and telehealth programs may quote you a cash price for ipamorelin. PeptideAgent lists none, for two reasons. There is no ipamorelin product to price: none is FDA approved, and a pharmacy has no federal basis to compound it. [1] [2] A quoted price is for a product FDA has not checked for safety, effectiveness, or quality, so it is not the price of a reviewed drug. [9]
If you're going ahead anyway: the checklist on the ipamorelin page. These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound ipamorelin, with or without a prescription. [2]
- Check the pharmacy's license
- What a legitimate prescription and consult look like
- Why this is safer than a research-use-only product
- Questions to ask the pharmacy, the telehealth company, the prescriber, and anyone offering it
What is the list price of ipamorelin?
There is no list price and no licensed channel. Offers that still appear are either outside FDA's stated compounding categories or research chemicals, which are unapproved drugs when sold for human use.
Does insurance cover ipamorelin?
Not covered; there is no approved or lawfully compounded product to cover.
What changes the price?
- Absence of any lawful compounding basis since the 2023 Category 2 placement and later 503A withdrawal
Frequently asked questions
How much does ipamorelin cost without insurance?
No lawful compounded price. Ipamorelin was placed on 503A Category 2 in September 2023, its 503A nomination was later withdrawn, and it is not on the bulks list or a component of an approved drug. Products sold as research chemicals for human use are unapproved drugs and are unverified for identity or purity. [1] [2] [4]
Does insurance cover ipamorelin?
Not covered; there is no approved or lawfully compounded product to cover. [3]
What is the list price of ipamorelin?
There is no list price and no licensed channel. Offers that still appear are either outside FDA's stated compounding categories or research chemicals, which are unapproved drugs when sold for human use.
Related pages
- Ipamorelin: evidence, legality, and access
- CJC-1295 vs ipamorelin (CJC-1295 cost)
- Ipamorelin vs GHRP-6
- Ipamorelin vs MK-677 (ibutamoren)
- Sermorelin vs ipamorelin (Sermorelin cost)
- Tesamorelin vs ipamorelin (Tesamorelin cost)
- Growth hormone deficiency and GH secretagogue use: peptide evidence
- Where it is legal to get: peptide law by state
- Full cost index
From the blog
- Ipamorelin side effects and benefits: what studies show
Ipamorelin side effects in its one human trial matched placebo, but FDA flags serious events with IV use. Claimed benefits for muscle, fat loss, and sleep are untested. Not FDA approved.
- Peptide stacks: what each common component has shown alone
No trial has tested a multi-peptide stack for muscle growth or fat loss. Nine common stack components ranked by their own human evidence, legal status, and WADA status. No protocols.
Sources
- [1]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list and withdrawn nominations, content current as of April 22, 2026)FDA
- [2]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA
- [3]Medicare.gov: prescription drug coverage (Part D and outpatient drugs)
- [4]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
- [5]FDA warning letter 594743, April 1, 2020, to a state-licensed 503A compounding pharmacy (FDA warning letters database)FDA, 2020
- [6]FDA warning letter 624782, January 26, 2022, to a compounding pharmacy (FDA warning letters database)FDA, 2022
- [7]FDA warning letter 733652, August 24, 2026, to an online seller of research-use-only peptides (FDA warning letters database)FDA, 2026
- [8]FDA briefing document, Pharmacy Compounding Advisory Committee, October 29, 2024 (includes ipamorelin)FDA, 2024
- [9]FDA: Compounding and the FDA, questions and answersFDA